Humana AB entered into a definitive agreement to acquire 100% of Coronaria Hoiva Oy to significantly expand its operational footprint in the Finnish market. This strategic acquisition was designed to integrate Coronaria Hoiva’s specialized residential care portfolio into Humana’s existing Finnish operations, creating a more diversified and robust platform for social care delivery. The transaction was financed through a combination of existing cash reserves and new credit facilities, and it received formal approval from the Finnish Competition and Consumer Authority in early April. The move aligned with Humana’s long-term strategy of consolidating the Nordic care market, providing an immediate positive contribution to the group's revenues and earnings per share while enhancing its ability to serve the growing Finnish aging population.

CORONARIA HOIVA, which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the average currently observed in the Healthcare & Pharma sector (13.3x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.